UBS Group
ESLA icon

UBS Group’s Estrella Immunopharma ESLA Stock Holding History

UBS Group’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79K Sell
1,721
-13,358
-89% -$17.5K ﹤0.01% 9470
2026
Q1 		$16K Buy
15,079
+11,892
+373% +$13.7K ﹤0.01% 8089
2025
Q4 		$4.97K Sell
3,187
-47,160
-94% -$89.3K ﹤0.01% 8749
2025
Q3 		$57.9K Sell
50,347
-22,426
-31% -$21.5K ﹤0.01% 7463
2025
Q2 		$69.9K Buy
72,773
+31,739
+77% +$30.8K ﹤0.01% 7516
2025
Q1 		$38K Sell
41,034
-24,133
-37% -$26.5K ﹤0.01% 7783
2024
Q4 		$78.2K Buy
65,167
+58,644
+899% +$59.1K ﹤0.01% 7030
2024
Q3 		$7.57K Buy
+6,523
New +$8.39K ﹤0.01% 7894
2024
Q1 		– Sell
-303
Closed -$336 – 9476
2023
Q4 		$336 Buy
+303
New +$458 ﹤0.01% 8718
2023
Q1 		– Sell
-756
Closed -$7.78K – 9787
2022
Q4 		$7.78K Buy
756
+310
+70% +$3.15K ﹤0.01% 8860
2022
Q3 		$4K Buy
+446
New +$4.48K ﹤0.01% 9349

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group's ESLA Position: Q2 2026 in Review

UBS Group reduced its Estrella Immunopharma (ESLA) stake by 89% in Q2 2026, selling an estimated $17.5K and leaving 1,721 shares worth $1.79K. The position accounts for ﹤0.01% of the portfolio, ranked #9470.

UBS Group first reported a position in ESLA in Q3 2022 and has held it in 11 quarters since. The position peaked at $78.2K in Q4 2024. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • UBS Group held 1,721 shares of Estrella Immunopharma worth $1.79K as of Q2 2026.
  • UBS Group sold 13,358 Estrella Immunopharma shares in Q2 2026, an estimated $17.5K.
  • Estrella Immunopharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9470 holding.
  • UBS Group first reported a position in Estrella Immunopharma in Q3 2022 and has held it in 11 quarters since.
  • UBS Group's Estrella Immunopharma position peaked at $78.2K in Q4 2024.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.